Aerie Pharmaceuticals, Inc.
NASDAQ: AERI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Vicente Anido
- Employees
- 376
- Headquarters
- Durham, United States
- IPO year
- 2013
- Website
- https://www.aeriepharma.com
Loading AERI…
Loading profile data…Frequently asked questions about AERI
What does Aerie Pharmaceuticals, Inc. (AERI) do?
Aerie Pharmaceuticals, Inc. operates as a pharmaceutical enterprise focused on the discovery, development, and commercialization of ophthalmic treatments for the U.S. market. The company's therapeutic scope includes open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration. Its commercialized portfolio featur...
Where does AERI trade?
Aerie Pharmaceuticals, Inc. (AERI) trades on the NASDAQ Global Market.
What sector is AERI in?
Aerie Pharmaceuticals, Inc. (AERI) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Aerie Pharmaceuticals, Inc.?
Vicente Anido is the chief executive officer of Aerie Pharmaceuticals, Inc. (AERI).
Where is Aerie Pharmaceuticals, Inc. headquartered?
Aerie Pharmaceuticals, Inc. is headquartered in United States.
Does AERI pay a dividend?
Aerie Pharmaceuticals, Inc. (AERI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AERI go public?
Aerie Pharmaceuticals, Inc. (AERI) completed its initial public offering in 2013.